## 10 Summary
\begin{table}
\begin{tabular}{c c c c c c c c} \hline \hline
**Matrix** & **Analyte** & **Sorption Phase** & **Detection** & **LOD** & **Recovery** & **RSD** & **Ref.** \\ \hline \multirow{8}{*}{Plasma} & Tricyclic antidepressants & MIP & LC-MS/MS & 1.0–5.0 ng mL\({}^{-1}\) & 90–110 & 15 & [62] \\ \cline{2-8}  & Antidepressant drugs: & \multirow{2}{*}{\begin{tabular}{c} PVA/CA/\(\beta\)- \\ Cloarginine, \\ Trimipramine \\ \end{tabular} } & \multirow{2}{*}{GC-FID } & \multirow{2}{*}{0.03–0.15 ng mL\({}^{-1}\)} & \multirow{2}{*}{78–95} & \multirow{2}{*}{5–7} & \multirow{2}{*}{[154]} \\  & & & & & & \\ \cline{2-8}  & & C18/PAN & LC-MS/MS & 0.08–0.2 ng mL\({}^{-1}\) & 83–98 & & [101] \\ \cline{2-8}  & & & & & & & \\ \cline{2-8}  & Anti-cancer drugs & \multirow{2}{*}{\begin{tabular}{c} Co-MOF- \\ 74/polyfam \\ \end{tabular} } & \multirow{2}{*}{HPLC-UV} & \multirow{2}{*}{0.03–0.20 \(\mu\)g L\({}^{-1}\)} & \multirow{2}{*}{-} & \multirow{2}{*}{3–9} & \multirow{2}{*}{[71]} \\  & & & & & & \\ \cline{2-8}  & & & & & & \\ \cline{2-8}  & & & & & & \\ \cline{2-8}  & & & & & & & \\ \hline \multirow{8}{*}{Plasma} & Carvedilol & g-C\({}_{3}\)N\({}_{4}\)/N\({}_{6}\) NC & FS & 1.0 ng mL\({}^{-1}\) & 87 & 3.6 & [158] \\ \cline{2-8}  & \begin{tabular}{c} Fentanyl, \\ methadone, zolpidem \\ \end{tabular} & \begin{tabular}{c} Octyl- \\ cyanopropyl/PAN \\ \end{tabular} & \begin{tabular}{c} HPLC- \\ MS/MS \\ \end{tabular} & 4.3–8.3 ng mL\({}^{-1}\) & 34–62 & \textless{}15 & [157] \\ \cline{2-8}  & Fluoxetine & GO/CS & \begin{tabular}{c} HPLC-UV- \\ Vis \\ \end{tabular} & 1.6 ng mL\({}^{-1}\) & 87 & \(\leq\)9 & [152] \\ \hline Oral fluid & \begin{tabular}{c} Fentanyl, \\ methadone, zolpidem \\ \end{tabular} & \begin{tabular}{c} Octyl- \\ cyanopropyl/PAN \\ \end{tabular} & \begin{tabular}{c} HPLC- \\ MS/MS \\ \end{tabular} & 4.8–9.6 ng mL\({}^{-1}\) & 27–38 & \textless{}15 & [157] \\ \hline Saliva & \(\beta\)-blockers & GO/PEG & LC-MS/MS & 1.25–8.00 nmol L\({}^{-1}\) & 80–109 & 4–13 & [87] \\ \cline{2-8}  & Methamphetamine & aptamer/CDs/cellulose & ESI-IMS & 0.6 ng mL\({}^{-1}\) & 87–108 & 6 & [107] \\ \hline \begin{tabular}{c} Exhaled air \\ condensate \\ \end{tabular} & Aldehydes & PS/G & HPLC & 3.8 nmol L\({}^{-1}\) & 80–106 & 16 & [86] \\ \hline Skin & \
\begin{tabular}{c} Volatile organic \\ compounds \\ \end{tabular} & PDMS & GC-MS & - & - & \textless{}9 & [37] \\ \hline \multirow{2}{*}{Fish tissue} & Polychlorinated & biphenyls & PDMS & LC-MS & - & - & [35] \\ \cline{2-8}  & Pharmaceuticals & \multirow{2}{*}{C18/PAN} & LC/MS-MS & 0.08–0.21 ng g\({}^{-1}\) & - & 9–18 & [102] \\ \cline{2-8}  & & & & & & \(\leq\)6 \\ \hline Fish plasma & Steroid hormones & \multirow{2}{*}{C18/PAN} & LC-MS/MS & 0.006–0.150 ng mL\({}^{-1}\) & - &
\begin{tabular}{c} \(\leq\)6 \\ \(\leq\)15 \\ \end{tabular} & [103] \\ \hline \hline \end{tabular}
\end{table} 
Table 15: _Cont._tivity in adsorption of analytes from complex matrices. In terms of selectivity, materials such as organometallic frameworks, aptamers, molecularly imprinted polymers take the spotlight. Tables 13-15, containing detection limits and analyte recoveries in microextractions, show that the above-described materials, used as sorption phases, provide selective microextractions and sensitive determinations with detection limits at the nanograms per liter level. As a result, TF-SPME is successfully used to prepare analytical samples to determine a vast spectrum of analytes in sample environmental, biological, and food matrices. For several years, commercial TF-SPME kits with sorption phases that enable the microextraction of polar as well as non-polar analytes have also been available and offered, among others, by GERSTEL and Markes International. The commercialization of TF-SPME devices could increase their use in analytical procedures carried out in both research and industrial laboratories in the coming years.